Navamedic ASA Broadens its Horizons with Acquisition in Addiction Treatment Sector

Navamedic ASA Enters the Addiction Treatment Market



In a strategic move to broaden its business portfolio, Navamedic ASA, a well-known Nordic pharmaceutical company, has recently entered into an agreement to acquire dne pharma, a firm specializing in addiction treatment pharmaceuticals. This acquisition, estimated at up to NOK 225 million, marks a significant step for Navamedic as it ventures into a critical and growing therapeutic area.

Details of the Acquisition



The acquisition will take place in installments, with NOK 185 million paid at closing and NOK 40 million in subsequent payments contingent on meeting specific sales targets for the acquired products. Navamedic aims to integrate dne pharma's robust product lineup, which includes essential medications like Ventizolve® for the emergency reversal of opioid overdoses, Levopidon® and Metadon Dne, commonly used in opioid substitution therapies.

CEO Kathrine Gamborg Andreassen stated, “This acquisition gives us a strong strategic position in an important therapeutic area. Addiction treatment has a profound impact on society, and dne pharma’s offerings align with our mission to provide high-quality products where they are most needed.”

The purchase not only helps in achieving Navamedic’s revenue target of NOK 1 billion but is also projected to enhance the company's gross margins once the new products are incorporated. With the expected annual EBITDA contribution of approximately NOK 25 million based on 2024's net sales, this venture is projected to yield significant financial benefits.

Financing the Acquisition



To finance this deal, Navamedic will secure NOK 110 million in new debt from Nordea Bank, alongside a partially underwritten rights issue aiming for gross proceeds between NOK 110 million and NOK 130 million. The rights issue will offer existing shareholders the chance to maintain their stakes, with arrangements made to maximize shareholder participation, guaranteeing the minimum amount underwritten by the largest shareholder, Kistefos AS.

The subscription price is set at NOK 21.50 per share, and shareholders are expected to receive tradable subscription rights proportional to their current holdings. The rights issue is conditional on approval at an extraordinary general meeting scheduled for July 14, 2025. If approved, the completion of the acquisition will take place shortly thereafter.

Strategic Integration and Future Outlook



This acquisition aligns with Navamedic’s long-term strategy of expanding its portfolio of proprietary products. With dne pharma’s business integrated into Navamedic's platform, quicker market access across Nordic countries and potential to expand into select European markets is anticipated. The new product range will not only complement existing offerings but is also expected to bring operational synergies in logistics, warehousing, and tender management.

Overall, this strategic endeavor positions Navamedic ASA advantageously within an industry that is increasingly recognizing the importance of addiction treatment. As addiction rates rise globally, the need for effective and accessible treatment options is more pressing than ever, and Navamedic aims to meet this demand head-on.

Navamedic's CEO further iterated, “The expansion into addiction treatment is not just a business opportunity; it’s a commitment to enhancing public health outcomes. Our goal remains to provide high-quality healthcare products where they are needed the most.”

This move significantly enhances Navamedic’s market presence and reinforces its reputation as a key player in the Nordic pharmaceutical landscape.

For more details about Navamedic and its latest initiatives, visit navamedic.com.

About Navamedic ASA


Navamedic ASA is a comprehensive healthcare product provider for pharmacies and hospitals across the Nordic region and is based in Oslo, Norway. The company prides itself on delivering top-quality healthcare solutions tailored to meet the needs of patients and healthcare providers.

About dne pharma


Dne pharma specializes in addiction and pain therapies, focusing on emergency overdose treatments and opioid substitution therapies. Its products play a vital role in public health strategies designed to combat addiction in Scandinavia and beyond.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.